

Session: 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents Presentation Number: L0184

Please access this presentation by scanning the QR code or via https://tago.ca/eccmid-12



Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology

S.J. R Arends¹, J West², J Thompson¹, N Scangarella-Oman², M Castanheira¹, <u>R Mendes¹</u>

¹ JMI Laboratories, North Liberty, Iowa, USA ² GlaxoSmithKline plc., Collegeville, Pennsylvania, USA

 This study at JMI Laboratories was supported by GlaxoSmithKline. JMI Laboratories received compensation fees for services in relation to preparing the poster.



 Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor in clinical development for the treatment of uncomplicated UTI (acute cystitis) and urogenital gonorrhea. This study evaluated combinations of gepotidacin and other antimicrobial agents for synergistic or antagonistic activity.

Study Design

- 5 isolates from each of the following species were evaluated:
 - S. saprophyticus, E. faecalis, E. coli, C. freundii, E. cloacae species complex, K. aerogenes, K. pneumoniae, P. mirabilis, and P. rettgeri
- Interactions between gepotidacin and 10 marketed antibiotics were studied by checkerboard broth microdilution method.
 - azithromycin, ceftazidime, levofloxacin, nitrofurantoin, tetracycline, trimethoprim/sulfamethoxazole, aztreonam, meropenem, linezolid, and vancomycin
- Minimum and maximum fractional inhibitory concentration (FIC) values were calculated for each combination.
 - FICs 0.5 : Synergy
 - FICs 0.5 4 : Indifference
 - FICs > : Antagonism
 - Indeterminate was assigned when combination effects could not be determined.



Codrug															
										A.	annoimycin	1			
5	4		5	4		5	5		5	Ir	ndifference	e a	5		5
0	1		0	1		0	0		0	S	Synergy		0		0
	Λ	5	5	stell Indi	IZ 0 M9		Λ	3		5		5		5	1
	4 1 		- -	••••••••••••••••••••••••••••••••••••••			+ • 1	5	14	- -	1 - 1 - 1 - 4 V	0		• •	+ -
lan an anan	۲	F	. Л	8.9°	5	ی جه	45	5	Indiffor		45°		4 P.	5	معند المعند ا
			<u>^</u>				^				^	-	<u> </u>	<u>.</u>	
1	= [<u></u>					_ <u>_</u>	<u>_</u>		<u>_</u>	<u></u>	<u>_</u>		<u></u>
<i>2</i> 3			<i>//</i> 3\					<u> </u>	A-3.		64 .		6%		
	5	5		F	Б		F	Б		٨		5		5	Tetracycline
0	Synergy	.	0	0	.)	0	0	.)	0	4	0	.)	1	.)	0
	5	Indifference		5	5		5		5	3	}	5		5	5
	0	0		0	0		Synergy		0		0		0	0	2
	5	Δ				F	Aztreonam Indifference		Δ		3		5	5	5
	^			U			Cup arou			गाच जुर	<u> </u>		<u>^</u>	20	•
	n a ar ar an	······································		్ భా భా భా భా			20.02		<i>y</i>		.4	A concerner conce	<u>- 4</u>		k
	1	1		0	0		1				S	Synergy		1	1
-		(.) 5#												l in amalia	J
<u> </u>		0		Svnerav											6
							Vana					× 20 m m			
		na ga ang ang ang ang ang ang ang ang ang ang ang ang ang ang							-			1 1.66			 ;
4	Syne	rgy													U
			·												
-		and the second of			18, 80, 800000 +• 		• • • • • • • • • • • • • • • • • • • •				<u></u>		=		

S. J. Ryan Arends, Ph,D, JMI Laboratories